Marketresearchnews

Monday, 17 September 2018

Breast Biopsy Market 2018 Share, Trend, Segmentation and Forecast to 2023

Market Scenario

The global breast biopsy market is expected to grow significantly during the forecast period (2018–2023).

A biopsy is a small operation performed to remove tissues from an area of concern in the body. Breast biopsy is a procedure that involves testing of small samples of breast tissues for detecting breast cancer. Breast biopsies are conducted using minimal invasive biopsy systems, owing to minimal disfigurement and pain.

There are different types of biopsy procedures depending on the technique, such as core needle biopsy (CNB), fine needle aspiration biopsy (FNAB), and vacuum-assisted biopsy (VAB) recommended by the doctor based on the location, size, and other characteristics of the breast abnormality.

The increase in the prevalence of breast cancer, especially among women above the age of 35 during menopause (are more susceptible to breast cancer) and growth in the awareness regarding breast cancer screening programs drive the market growth. However, unspecified regulatory issues, infection risks connected with breast biopsy procedures, and ambiguous reimbursement policies are the factors limiting the market growth. Additionally, restraints for the market include the high cost of surgical procedures and risks involved in them. Conversely, the emergence of technologically-advanced and minimally invasive breast biopsy devices are expected to provide lucrative opportunities in the untapped market.

Segmentation

The global breast biopsy market has been segmented on the basis of product, technique type, guidance technology, and end-user.

On the basis of product, the market has been classified as biopsy needles, biopsy tables, biopsy wires, guidance systems, and others.

On the basis of technique type, the market is classified into fine needle aspiration biopsy, core needle biopsy, biopsy markers, MRI-guided core needle biopsy, surgical biopsy, wire localization, and sentinel node biopsy. Further, core needle biopsy is divided into stereotactic core needle biopsy, vacuum-assisted biopsy, ultrasound-guided core biopsy, and freehand core-needle biopsy. Surgical biopsy is segmented into incisional biopsy and excisional biopsy.

On the basis of guidance technology, the market is classified into ultrasound-guided, mammography-guided magnetic resonance, CT-guided biopsy, and other image-guided breast biopsy (PET and thermography).

On the basis of end-user, the market is divided into hospitals, ambulatory surgical centers, diagnostic centers, and others.

On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European breast biopsy market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The breast biopsy market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The breast biopsy market in the Middle East and Africa has been segmented into the Middle East and Africa.

Regional Market Summary

In the breast biopsy market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies and continuous development by companies operating in cancer diagnostics. The global breast biopsy market is largely focused on North America and Europe, which is valued to account for more than 50% of the market share.

The European market is expected to hold the second largest market share as breast cancer is most common in the UK and Belgium. According to the Cancer Research UK in 2015, 55122 new cases of invasive breast cancer were diagnosed.

The market share in the Asia-Pacific region is also projected to experience growth in the near future due to access to optimal treatment facilities, growing demand for advanced technology, better adoption rate, increasing government initiatives, and rising healthcare expenditure.

The market in the Middle East and Africa is expected to account for the smallest share of the global breast biopsy market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Key Players

Some of the key players in the global breast biopsy market are Leica Biosystems, C.R. Bard Inc., NuVue Therapeutics, Argon Medical Devices, Inc., Becton, Dickinson and Company, Devicor Medical Products Inc. Hologic Inc. Argon Medical Devices, Cook Medical Incorporated, Encapsule Medical Devices LLC., Johnson & Johnson, Galini SRL, Intact Medical Corporation, Conceptus INC, Hologic Inc., Karl Storz GmbH & Co. Kg, GE Healthcare.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6288

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Palliative Care Market, Segments, Growth and Value Chain 2018

Market Scenario

Global Palliative Care market is expected to grow during the forecast period (2018–2023) at a CAGR ~8.1 %.

Palliative care helps to improve the quality of life of patients and their families facing the problems of serious illness. The main focus of Palliative care is to provide relief from symptoms and stress of a serious illness. Their main goal is to improve the quality of life for both the patient and the family. Palliative care treats people living with a serious illness such as cancer, cardiac diseases such as congestive heath failure, kidney failure, Alzheimer’s and many more. It improves the quality of life of the patient and supports the primary physician, patient, and family. In last 15 years, the Palliative care market has a stunning growth and the factors that have led to the growth of this market are growing the aging population, increase in chronic life-threatening disease, initiative taken by the government and non- profit organization, and rise in government funding.

However, the high cost of treatment, misuse of funding and lack of awareness are some of the factors which are hampering the growth of the market during the forecast period.

Segmentation

The Global Palliative Care Market is segmented into types such as private residence care, hospice inpatient care, hospital inpatient care, nursing home and residential facility care and others. On the basis of application, the market is further segmented into cancer, cardiac diseases such as congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), kidney failure, Alzheimer’s, Parkinson’s, Amyotrophic Lateral Sclerosis (ALS) and many more. On basis of end-user, the market is further segmented into hospitals, home care settings, palliative care centers, long-term care centers & rehabilitation centers.

The market has been segmented, by region, into the Americas, Europe, Asia Pacific, and the Middle East and Africa. The Global Palliative Care Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European Global Palliative Care Market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Global Palliative Care Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Palliative care market in the Middle East and Africa has been segmented into the Middle East and Africa.

In terms of market value, North America will dominate the Palliative care market during the forecast period. Increasing incidences of life-threatening illness such as cancer, cardiovascular diseases, Alzheimer’s disease, kidney failure, chronic obstructive pulmonary disease and many more are some of the factors which are responsible for the growth of the market during the forecast period. In 2015 on average 90 % of US hospitals containing 300 beds or more provide Palliative care services to their patients. This has led to the growth of the market in coming years. The European market is expected to be the second-largest Palliative care market. The market growth in this region can be attributed to government funding and support of the healthcare sector coupled with increasing research and development. Moreover, a growing number of Palliative care centers worldwide, extending application for homecare, increasing number of qualified physicians for Palliative care center and expanding aging demographics are some of the factors responsible for the rise in the global Palliative care market. Asia-Pacific is expected to be the fastest-growing Palliative care market during the forecast period owing to the increasing prevalence of cardiac diseases, rising investments in healthcare, increasing geriatric population, and expansions by market players in the region. Asia-Pacific is giving the strong competition in the global Palliative care market by producing a cost-effective treatment that is high in demand in local as well as in the global market. The market in the Middle East and Africa is expected to account for the smallest share in the global Palliative care market due to the underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Key Players

Some of the key players in the Global Palliative Care market are Vitas Healthcare Corporation, Skilled Healthcare Group Incorporated, Sunrise Senior Living LLC, Kindred Healthcare Incorporated, Gentiva Health Services Incorporated, Home Instead Senior Care Incorporated, Amedisys Incorporated, Genesis HealthCare Corporation.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6336

Psoriasis Treatment Market 2018–By Identifying the Key Market Segments and Key players holding market share

Synopsis of Global Psoriasis Treatment Market

Market Scenario

Psoriasis is a chronic non-contagious disease in which a person’s immune system sends faulty signals directing skin cells to grow too quickly. New skin cells forms in days rather than weeks resulting in their pilling up on the surface of the skin, causing patches of psoriasis. Most of the time it also affects fingers and nails resulting in painful disfiguration and partial disability. Psoriasis affects mostly knees, elbows, and scalp, but other body parts may also be affected. Thus, it has a heavy negative effect on the quality of life and results in social stigma. Although it can occur at any age but most commonly it occurs in the age group of 50–70. The exact cause and etiology of psoriasis is still unknown but usually auto-immunity, genetics and environmental factors are involved. Psoriasis is also associated with a host of co-morbidities such as psoriatic arthritis, ophthalmologic pathologies, diabetes, inﬂammatory bowel disease etc. According to the World Health Organization (WHO), 1.3% to 34.7% of individuals with psoriasis develop chronic psoriatic arthritis which may lead to joint deformations and disability. From 4.2% to 69% of all patients suffering from psoriasis develop nail changes. WHO also predicts that psoriasis affects about 100 million people with prevalence rates ranging from 0.09% to 11.43% in different countries. Plaque psoriasis is the most common form of psoriasis affecting 90% of all cases of psoriasis.

Rise in screening and growing prevalence of psoriasis remains the most critical market driving factor of the global psoriasis treatment market. In general an upward trend is observed in several countries throughout the world. For example data from the national health and nutrition examination survey revealed that in United States prevalence of psoriasis increased from 1.62% to 3.10% from 2004 to 2010.

The other market driving factors for the global psoriasis treatment market is growing awareness, rise in risk factors such as autoimmune diseases, diabetes etc. and greater exposure to environmental factors such as chemicals, allergens etc. The market’s constraints include lack of effective and permanent treatment for the disorder. There is no cure for psoriasis and most treatment is either symptomatic or is temporary in nature. Other market restraints include high cost of drug development, patent expiry of a number of blockbuster drugs such as humira, enbrel and remicade etc, side effects associated with present medications such as hypertension, liver and kidney damage etc. The high cost of drugs coupled with their low efficacy and the advent of biosimilars also hampers the growth of the market.

The latest market trends include huge potential reflected by novel acting biologics such as TNF-α inhibitors, IL-17 inhibitors etc. The psoriasis treatment market also favors companies with a strong research pipeline. Thus novel drug development especially involving biologics will be the best strategy and will lead to fast growth of the market along with least marketing expenditure. Thus product development is the critical strategy to be a market leader of global psoriasis treatment market.

The global psoriasis treatment market was valued to be US$7.0 billion in 2016 and is expected to reach US$10.68 billion by 2022. Thus the market is expected to grow at a CAGR of 7.3% from 2016 to 2022.

Study Objectives Global Psoriasis Treatment market:

To provide detail analysis of the market structure along with forecast for the next 6 years of the various segments and sub-segments of the global psoriasis treatment market.
To provide insights about factors affecting the market growth.
To analyze the market based on various analyses which includes price analysis, supply chain analysis, Porters Five Force analysis etc.
To provide past and estimated future revenue of the market’s segments and sub-segments with respect to four main geographies and their countries including Americas, Europe, Asia-Pacific, and Middle East & Africa.
To provide country level analysis of the market with respect to the current market size and future growth prospect.
To provide country level analysis of the market for segments by mechanism of action (TNF inhibitors, phsophodiesterase inhibitors, interleukin blockers and others), by route of administration (oral, tropical and injectable) and by drug types (small molecules and biologics)
To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies and drawing a competitive landscape of the market
To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments globally.

Key Players for Global Psoriasis Treatment Market

Some of the key players of this market are namely Novartis International AG, Johnson & Johnson, Pfizer Inc, Merck and Co. Inc, AbbVie and Amgen and Eli Lilly.

Segments

Global psoriasis treatment market has been segmented on the basis of mechanism of action, route of administration and by drug types.

Regional Analysis of Global Psoriasis Treatment Market

Globally North America is the largest market of global psoriasis treatment. Europe is the second largest market for global psoriasis treatment. However the developing market is Asia Pacific that will be the fastest growing region and will be the key to the future.

The report of global psoriasis treatment market by Market Research Future comprises extensive primary research along with detail analysis of qualitative as well as quantitative aspects by various industry experts and key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size in terms of value & volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies followed by top key players in the industry. The report also gives a broad study of different markets segments and regions.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/2769

Cell Isolation Market Top Trends, Regulations and Competitive Landscape Outlook To 2023

Market Snapshot

Cell isolation is viewed as a highly sophisticated process, which has tremendous potential. It is currently used for understanding how cells function. Physicians are also employing cell isolation to find out how cells respond to different diseases and how they are affected by different drugs. In 2017, the global market for cell isolation stood at USD 4, 098.5 Mn and is likely to surpass a valuation of USD 10,500 Mn by the years 2023. While cell isolation is already being considered for treatment purposes, its application is likely to proliferate to various other fields of healthcare science in the future. Cell culture, a process of multiplication of cells to create a cell colony also involves cell isolation. Other factors that are anticipated to support the growth of the cell isolation market include rising cancer prevalence, increased government funding for cell-based research and advances in cell analysis techniques.

Report Overview

This MRFR market perspective delivers an exhaustive assessment of the current trends in cell isolation process and its market opportunities. It also includes a discussion on the key market dynamics such as drivers and critical restraints that are influencing or disrupting the cell isolation market landscape. A revenue analysis on various sub-markets is also available in research document, which will enable investors to identify revenue pockets that are likely to remain highly lucrative throughout the review period. Major types of product used for cell isolation process covered in the report include consumables and instruments. The overall market sizing based on cell types covers human cells and animal cells. Centrifugation-based cell isolation, surface marker-based cell isolation and filtration-based cell isolation are the major techniques profiled in the report. The currently application areas identified include biomolecule isolation, cancer research, stem cell research, tissue regeneration, in vitro diagnostics and therapeutics. A revenue analysis based on primary end-users (research laboratories and institutes, biotechnology and biopharmaceutical companies, hospitals and diagnostic laboratories, and cell banks) is also available.

Report Coverage

Value, Market Share, Player Analysis, supply chain analysis, Porter's five forces model, demand & supply: gap analysis, investment opportunities analysis, pricing analysis, country level break down for product, cell type, technique, application, end-user.

Players Covered

Thermo Fisher Scientific Inc., GE Healthcare, Becton, Dickinson and Company, Beckman Coulter, Merck KGaA, STEMCELL Technologies, Miltenyi Biotec, TERUMO CORPORATION, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG.

Research Methodology

Market Research Future (MRFR) makes comparative assessment of all the market parameters on multiple levels to deliver a macro overview. The projections are made after an in-depth study of various elements such as historical market trends, key developments, and, shifts in consumer behavior. Robust scientific methods are employed for ascertaining the statistical observations. The fail-safe interpretation of data is backed by credible inputs sourced through primary and secondary research which includes interviews with stakeholder across the value chain (CEOs, Business Development Managers, Vice Presidents, etc.), white paper references, research publications, and, reports published by national and international organizations among others. A multi-layer verification process authenticates market forecast and ensures cross-verification of information delivered. Top-down and bottom-up approaches are employed to validate the accuracy of the market size and revenue estimation. MRFR uses innovative and sound analytical algorithms for ensuring the optimum quality of research findings.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6193

Wednesday, 12 September 2018

Magnetic Resonance Imaging (MRI) Market Global Segmentation and Major key Players Analysis 2023

The Global Magnetic Resonance Imaging (MRI) Systems market is expected to be of value USD 5 Billion in 2023 and to grow at a depict 3.5% CAGR during the forecast period.

Magnetic Resonance Imaging (MRI) Systems Market Key Players:

Market Research Future (MRFR) recognizes the following companies as the key players in the magnetic resonance imaging (MRI) systems market. Some of the players are Hitachi, Siemens AG, Canon Medical Systems, GE Healthcare, Philips, Toshiba Corporation, Toshiba Corporation, Xingaoyi, Aurora Imaging Technologies, Inc.

Market Scenario:

Magnetic resonance imaging (MRI) systems is a non-invasive technique in which light is used to interrogate cellular and molecular function in the living body by exploiting the special properties of photons. Magnetic resonance imaging (MRI) systems are surpassing the radiology imaging market due to its myriad advantages over it. This market is mainly driven by rising demand for non-invasive procedures, harmful effects of radiation-based imaging, increase in research and development activities in the life sciences sector, and increasing application of magnetic resonance imaging (MRI) systems techniques in drug discovery processes and preclinical research, Moreover factors such as rising geriatric population which leads to increase in cardiovascular, neurological and ophthalmic disorders is also fueling the growth of this market. However, the market growth is restricted by factors such as stringent regulatory approval procedures high costs of instruments, scarcity of skilled operators, and insufficient reimbursements policies for magnetic resonance imaging (MRI) systems procedures.

Market Segmentation:

The global magnetic resonance imaging (MRI) systems market is segmented on the basis of type, field strength, disease application and end user.

Considering the type, the market is segmented into open MRI, closed MRI, standard bore MRI, wide-bore MRI.

On the basis of field strength, the market is segmented into high-field MRI systems, 1.5t MRI systems, 3t MRI systems, low-to-mid-field MRI systems, very-high-field MRI systems, and others.

On account of disease application, the market is segmented into the spine and musculoskeletal MRI, brain and neurological MRI, pelvic and abdominal MRI, breast MRI, cardiovascular MRI, and others

According to the end user, the market is segmented into diagnostic imaging centers, hospitals and clinics, research laboratories, and pharmaceutical &biotechnology companies.

Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.

Regional Market Summary:

In terms of geography, Americas dominates the market for Magnetic Resonance Imaging (MRI) systems owing to increasing prevalence of cardiovascular, neurological and ophthalmic disorders pertaining to rising geriatric population which is a major trigger factor for this disease. Additionally, factors such as increasing government initiatives and funding for research in the medical devices sector, rising demand for accurate diagnosis, awareness about adverse effects of radiation imaging, ability to provide in-depth images of soft tissues and vascular systems, and the presence of pharmaceutical giants also propel the market growth in this region. For instance, according to National Center for Health Statistics report in 2016, around 140,323 mortality occurred due to cerebrovascular disease or stroke in the US Thus, this rising patient pool is going to boost up the market growth during the forecast period.

Europe accounts for the second largest market and holds a healthy share in the global magnetic resonance Imaging (MRI) systems market due to major driving factors like availability of advanced treatment facilities, increasing healthcare expenditure, good healthcare infrastructure and flourishing medical device industry due to the presence of major market players. Additionally, knowledge about the benefits of Magnetic Resonance Imaging (MRI) Systems over radiation imaging and capability of inhabitants to afford the diagnostics is spurring the market growth.

Asia Pacific is expected to be the fastest growing market with most promising growth possibilities. According to a report published by the Department of Neurology in 2014, it is estimated that for the current population of 1.27 billion, approximately 30 million people suffer from neurological disorders in India. Thus, owing to the huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, availability favorable insurance policies market growth will be accelerated during the forecast period. Moreover, due to lower cost of clinical trials and research key players have been setting up their regional headquarters and manufacturing plants in Singapore, China, Japan, Korea, and Australia which make a positive growth curve in Magnetic Resonance Imaging (MRI) Systems market in future.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6194

The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates and Saudi Arabia is the largest market share owing to the development of healthcare industry and rising availability of specialty care centers. Hence, the market might show steady growth due to Saudi Arabia, the UAE market growth, and government initiatives to improve quality of healthcare in the Africa region.

Legg-Calve-Perthes Disease Market Global Segmentation and Major key Players Analysis 2023

Market Scenario

The global legg-calve-Perthes disease treatment market is expected to register a significant growth during the forecast period (2018–2023).

Legg-calve-perthes is a disease which occurs when the blood supply to the femoral head (upper end of the thigh bone) which fits in the hip socket temporarily stops to flow. As an outcome, the femoral head is no longer round and does not move smoothly in the hip socket, resulting in hip pain and constrained leg movements.

Legg-calve-perthes disease (LCPD) generally occurs in children of age 4 to 10 years. Individuals suffering from the disease go on developing a painful joint disorder called as osteoarthritis in the hips at an early age. Individuals suffering from the legg-calve-Perthes disease are often short compared to healthy individuals due to bone anomalies.

Major factors such as rising frequency rate in Perthes disease and increasing awareness about the Perthes disease boosts the market rate exponentially. Furthermore, the advancement of technology such as point-of-care drug delivery systems and focus on delivering good quality of life are some of the factors contributing to the growth of the market. Not identifying and treating the Perthes disease at initial stages are major restrains for the growth of the market.

Segmentation

The global legg-calve-Perthes disease treatment market has been segmented on the basis of type, application, age group, and end-user.

On the basis of type, the market has been classified as non-surgical and surgical methods. The non-surgical method is segmented into anti-inflammatory medications, casting and bracing, crutches, and others. casting and bracing is further segmented into Newington brace, Toronto orthosis, Scottish rite orthosis, broomstick plasters, and Birmingham orthosis. The others segment is further segmented into conventional calipers, Snyder slings, slings with crutches, and traction. The surgical method is segmented into femoral osteotomy, innominate osteotomy, a combination of femoral osteotomy, and innominate osteotomy.

On the basis of application, the market has been classified as hip Fracture, hip dislocation, osteoarthritis, and congenital dysplasia of the hip.

On the basis of age group, the market has been classified as 4 to 6 years, 6 to 11 years, 12 to 19 years, and others.

On the basis of end-users, the market has been classified as hospitals, clinics, ambulatory surgical centers, and others.

On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.

The European legg-calve-Perthes disease treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The legg-calve-Perthes disease treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The legg-calve-Perthes disease treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.

Regional Market Summary

Global Legg-Calve-Perthes Disease Treatment Share, by Region, 2017 (%)

Source: MRFR Analysis

In the legg-calve-Perthes disease treatment market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, the rise in awareness, the rise in growth of the healthcare sector, and also due to the rise in frequency of osteoarthritis.

The European market is expected to hold the second largest market share. The market growth in this region can be attributed to government funding and support from the healthcare sector coupled with increasing research and development.

The market share in Asia-Pacific is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increase in disposable income, and rising medical tourism.

The market in the Middle East and Africa is expected to account for the smallest share of the global legg-calve-Perthes disease treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6345

Key Players

Some of the key players in the global legg-calve-Perthes disease treatment market are BASF, Albemarle, Sunline, IOLCP, Shandong Xinhua Pharmaceutical Co. Ltd, Dr. Reddy's, DePuy Synthes, Prime Medical, Zimmer, Biomet Holdings, Inc., 3M Healthcare, Össur Hf, DJO, and Stryker Corporation.

Transthyretin Amyloidosis (ATTR) Market Revenue, Opportunity, Forecast and Value Chain 2018

Market Scenario

The Transthyretin (TTR) amyloidosis market is expected to register a sturdy growth during the forecast period. Transthyretin (TTR) amyloidosis is a medical condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in a body's organs and tissues. It generally affects peripheral neuropathic or autonomic neuropathy system and cardiac system. The cardiac form of Transthyretin (TTR) amyloidosis puts patients at the risk of arrhythmia, cardiomegaly, and orthostatic hypertension. The global ATTR market is likely to exhibit a robust growth during the forecast period due to the probability of rising number of ATTR therapeutic drugs launches, increasing African-American population as they are genetically susceptible to amyloidosis, increasing healthcare awareness among people, and rising average income of individuals. However, the growth of this market can be hindered by stringent regulatory policies, the high cost of ATTR drugs, incorrect diagnosis of ATTR disorders and limitations of clinical trials. Lack of knowledge about this condition and unavailability of advanced diagnostic methods in the middle-income countries are the major challenges to the market.

Market Players

Alnylam Pharmaceuticals
Pfizer
Merck
Ionis Pharmaceuticals Inc.
Corino Therapeutics Inc
Arcturus Therapeutics
Proclara Bioscience

Market Segmentation

The global Transthyretin (TTR) amyloidosis market is segmented on the basis of disease type, treatment, gender, and end-user. Considering the type of disease, the market is segmented into Transthyretin (TTR) familial amyloid polyneuropathy, Transthyretin (TTR) familial amyloid cardiomyopathy, and others. On the basis of treatment, the market is segmented into small molecules treatment, RNAi therapy, organ transplantation, and others. Small molecules treatment is further segmented into tafamidis and diflunisal. On gender basis, it is segmented into male and female. According to end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, and others.

Regional Market Summary

Americas dominates the market for Transthyretin (TTR) amyloidosis owing to the increasing prevalence of amyloidosis among adults and older population and rising geriatric population which is a major trigger factor for this disease. For instance, according to a report published by ASCO Journal in 2016 around 4,000 people developed amyloidosis each year in the United States. Thus, this rising patient pool is going to boost up the market growth during the forecast period. Additionally, factors such as increasing government initiatives and funding for research, development in advanced medical treatment options, and rising use of technologically advanced medical diagnostic devices are likely to drive the market. The presence of pharmaceutical giants such as Pfizer, Merck, etc. also propels the market growth in this region.

Europe is the second largest market and holds a healthy share in the global Transthyretin (TTR) amyloidosis market. The European market is expected to exhibit robust growth during the forecast period due to major driving factors such as availability of advanced treatment facilities, increasing healthcare expenditure along with growing need for better healthcare infrastructure, and government initiatives of healthcare reform. It is reported that in the U.K., around 60 new cases of Transthyretin (TTR) amyloidosis are reported annually, and the age-specific incidence rate of it is between 5.1 and 12.8 per million per year. Additionally, established medical device market and capability of inhabitants to afford diagnostics are aiding the market growth. However, the inefficacy of treatment and wrong diagnosis are hampering the market growth of this region.

Asia Pacific is expected to be the fastest growing market. According to a report published by the United Nations in 2015the number of older people aged 60 years or over in the world is predicted to grow by 56% between 2015 and 2030, out of which 66% of the older population would reside in the Asia Pacific region. This makes the region prone to Transthyretin (TTR) amyloidosis as chances of its prevalence increases with the increasing age. Owing to a huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, and availability favorable insurance and reimbursement policies, the market growth will be accelerated during the forecast period. Moreover, key players such as Pfizer, Merck, etc. have been setting up their regional headquarters and manufacturing plants in countries such as Singapore, China, Japan, Korea, and Australia. Thus, the growth curve of the Transthyretin (TTR) amyloidosis market will see a positive trend of growth.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6155

The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates and Saudi Arabia are the largest markets owing to the development of the healthcare industry and rising availability of specialty care centers. But the market might show a steady growth due to the genetical susceptibility of Africans for transthyretin amyloidosis and government initiatives to improve the quality of healthcare in this region.